December 16, 2025
NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® Device
November 18, 2025
NeuroSigma Launches Next-Generation Monarch Device for Pediatric ADHD After Successful Pilot Program
November 03, 2025
» NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity
June 10, 2025
» NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
April 30, 2025
» NeuroSigma Announces New Clinical Trial of Monarch eTNS System for Treatment of ADHD in Children with Fetal Alcohol Syndrome at UCLA
January 22, 2025
» NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental Disorders
January 13, 2025
» Clinical Trial of NeuroSigma's Monarch eTNS System for ADHD at King’s College London Completes Enrollment
December 11, 2024
» New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark's Center for Evidence-Based Psychiatry
May 09, 2024
» NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
January 18, 2024
» NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
November 07, 2023
» NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
October 03, 2023
» NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
July 12, 2023» NeuroSigma Establishes Singapore Subsidiary
March 01, 2023
» NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD
January 31, 2023
» NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
November 08, 2022
» NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD
October 17, 2022
» NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
September 27,2022
» NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System
June 14, 2022
» NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD
April 7, 2022
» NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to Date
February 22, 2022
» NeuroSigma Receives FDA Breakthrough Device Designation for Monarch eTNS System®
January 25, 2022
» Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction
January 11, 2022
» NeuroSigma Announces Promotion of Dr. Colin Kealey to President
December 8, 2021
» NeuroSigma Announces a $5 Million Equity Investment by KT Corporation
June 14, 2021
» KT and NeuroSigma Announce Strategic Digital Health Partnership
March 11, 2021
» NeuroSigma Continues to Build a Substantial Global Bioelectronics Patent Portfolio
January 22, 2021
» NeuroSigma Successfully Obtains HCPCS Codes from CMS for the Monarch eTNS System
